Trial | NCT01235819  Report issue

Official Title

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    20
To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.
Inclusion criteria T1DM <3 months GAD Antibody+ Stimulated C peptide<0.5ng/ml Ketosis at onset Age < 30 yr Exclusion criteria Age > 30 yr Pancreatic disease significant systemic complication
Study Started
Nov 30
2010
Primary Completion
Sep 30
2011
Study Completion
Sep 30
2011
Last Update
Jul 27
2016
Estimate

Drug Insulin

Exenatide Sitagliptin

  • Other names: Premixed Insulin

Drug Sitagliptin

Sitagliptin 100 mg per day oral

  • Other names: DPP 4 inhibitors

Drug Exenatide

Exenatide 10 micrograms daily twice

  • Other names: GLP 1 analogues

Insulin alone Active Comparator

Type 1 DM only on Insulin

Insulin and Exenatide Active Comparator

Newly detected Type 1 DM on Insulin and exenatide

Insulin and Sitagliptin Active Comparator

Newly detected Type 1 DM using Insulin and Sitagliptin

Criteria 

Inclusion Criteria:

T1DM <3 months
GAD Antibody+ or Stimulated C peptide<0.5 ng/ml
Ketosis at onset
Age < 30 yr

Exclusion Criteria:

Age > 30 yr
Pancreas disease
Significant systemic disease
No Results Posted